On The Path To Regeneration: NovaGo’s New Approach To Stroke
Executive Summary
Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.
You may also be interested in...
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates
The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.
UK Parliamentarians Call For A New, Internationally Competitive Pricing System
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.